Intrinsic Value of S&P & Nasdaq Contact Us

Aion Therapeutic Inc. ANTCF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • CA • USD

SharesGrow Score
13/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Aion Therapeutic Inc. (ANTCF) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 12/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $367,479, +0%/yr average growth. Net income is $6M (loss), growing at -734.2%/yr. Net profit margin is -1710.9% (negative). Gross margin is 44.4% (+0 pp trend).

Balance sheet: total debt is $2M with negative equity of -$4M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 0.12 (tight liquidity). Debt-to-assets is 296.2%. Total assets: $702,861.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 0/100 (Fail), Moat 39/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

ANTCF SharesGrow Score Overview

21/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 0/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 39/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Stock Chart & Stats

Market Data
52-Week Range0.0013-0.0197
Volume10K
Avg Volume (30D)41
Market Cap$2.07M
Beta (1Y)-0.53
Share Statistics
EPS (TTM)-0.02
Shares Outstanding$265.07M
IPO Date2021-04-21
CEOJohn Graham Simmonds Jr.
Financial Highlights & Ratios
Revenue (TTM)$367.48K
Gross Profit$163.12K
EBITDA$-6.07M
Net Income$-6.29M
Total Cash$68.34K
Total Debt$2.08M
Net Debt$2.01M
Total Assets$702.86K
Price / Earnings (P/E)-0.1
Price / Sales (P/S)5.64
Analyst Forecast
Company Info
CountryCA
ExchangeOther OTC
CurrencyUSD
ISINCA00905T1021

Price Chart

ANTCF
Aion Therapeutic Inc.  ·  Other OTC
Healthcare • Drug Manufacturers - Specialty & Generic
0.00 52WK RANGE 0.02
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message